ARTICLE | Company News
Biogen Idec, SurroMed deal
March 15, 2004 8:00 AM UTC
The companies extended their 2002 deal, under which SurroMed is characterizing the responses of multiple sclerosis (MS) patients to BIIB's Avonex interferon beta-1a (see BioCentury, June 24, 2002). ...